Myelodysplastic syndromes (MDS) are neoplasms with high molecular, biological, and clinical heterogeneity. 1,2Consequently, conducting basic, translational, and clinical research on MDS has historically been challenging and the field has lagged behind in terms of achieving significant therapeutic advances.
No takes yet. Share an insight, caveat, or question.
Stahl et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: